U.K. Prime Minister David Cameron called for the European Union to open talks with China on a full-scale trade deal, as the bloc seeks to curb Chinese goods that EU officials say are being dumped and subsidized.
GlaxoSmithKline Plc’s third-quarter sales of pharmaceuticals and vaccines in China fell 61 percent after an anti-corruption probe began there in July, and the drugmaker gave no outlook on how long the downturn would last.
When 100 of the top lung doctors in the U.S. gathered at a Hilton hotel in Houston last month to learn about GlaxoSmithKline Plc’s new respiratory drug, one message rang loud and clear: don’t ignore the pneumonia risk.
GlaxoSmithKline Plc Chief Executive Officer Andrew Witty said the U.K. drugmaker commissioned an independent review to investigate the root cause of alleged fraudulent behavior among senior executives in China.
Antony Odell needed to raise money for a biotechnology company with 19 employees and no sales, not an easy task in the U.K. Enter Neil Woodford, a star investor overseeing $51 billion at Invesco Fund Managers Ltd.
GlaxoSmithKline Plc is adding new products in China and hiring “a few hundred” more salespeople to promote them, betting that health-care reforms will widen access to drugs and make up for state-mandated price cuts.